Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) will release its Q1 2021 financial results and provide a pipeline update on May 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results. The company offers personalized genomic tests for skin cancer, including melanoma and squamous cell carcinoma. Stakeholders can access the live event online or by phone. Castle Biosciences is focused on improving cancer treatment decisions through genomic insights.

Positive

• Upcoming release of Q1 2021 financial results and pipeline update.
• Offers personalized genomic tests for several types of skin cancer.

Negative

• None.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the first quarter 2021 and provide a pipeline update, after the close of market on Monday, May 10, 2021.

Company management will host a conference call and webcast to discuss its financial results and pipeline update at 4:30 p.m. Eastern time on the same day.

Conference Call and Webcast Details

A live webcast of the conference call can be accessed here: https://edge.media-server.com/mmc/p/p5gxkbjh or via the webcast link on the Investor Relations page of the Company’s website (https://ir.castlebiosciences.com/investors). Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company’s website until March 29, 2021.

To access the live conference call via phone, please dial 877-282-2581 from the United States and Canada, or +1 470-495-9479 internationally, at least 10 minutes prior to the start of the call, using the conference ID 6526639.

There will be a brief Question & Answer session following management commentary.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx^®-Melanoma, DecisionDx^®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx^®-SCC), suspicious pigmented lesions (DecisionDx^® DiffDx™-Melanoma) and uveal melanoma (DecisionDx^®-UM, DecisionDx^®-PRAME and DecisionDx^®-UMSeq). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005270/en/

FAQ

When will Castle Biosciences release its Q1 2021 financial results?

Castle Biosciences will release its Q1 2021 financial results on May 10, 2021, after market close.

What time is the Castle Biosciences conference call?

The conference call will be held at 4:30 p.m. Eastern time on May 10, 2021.

How can I access the Castle Biosciences webcast?

You can access the live webcast of the Castle Biosciences conference call on their Investor Relations page or via a provided link.

What services does Castle Biosciences offer?

Castle Biosciences offers genomic tests for skin cancers, including melanoma and cutaneous squamous cell carcinoma.